Documenting Wound Biofilm for Accurate Debridement Billing

Wound biofilm documentation is the single most overlooked gap between sound clinical practice and defensible debridement billing. When a Medicare Administrative Contractor reviews your debridement claims, the first thing they look for is evidence that the wound warranted the procedure — and for chronic wounds, that evidence starts with biofilm.

Biofilm is present in an estimated 60–80% of chronic wounds that fail to progress. Yet most clinical notes describe only surface appearance: "wound bed with slough," "moderate exudate," "no signs of acute infection." That language leaves auditors with no clear basis for the debridement CPT code submitted, even when the clinical decision was entirely appropriate.

This guide breaks down how to document biofilm in a way that ties directly to Medicare's medical necessity standards and the CPT codes you bill.

Why Wound Biofilm Documentation Underpins Medical Necessity

Medicare LCDs for wound care services require documentation of wound characteristics, clinical rationale for treatment, and expected benefit. When billing selective debridement (CPT 97597) or surgical excisional debridement (CPT 11042 or higher), the note must establish why that level of debridement was medically necessary — not just that it was performed.

Biofilm is a well-established reason for repeated debridement. The extracellular polymeric substance (EPS) matrix that biofilm bacteria produce re-forms within 24–72 hours of disruption. That biological reality is the direct clinical rationale for a maintenance debridement schedule. If notes don't capture that reasoning, a claim for a second or third debridement on the same wound looks like overutilization to a payer.

For a full review of what MACs check in wound care claims, see the wound care LCD compliance guide.

Clinical Signs to Capture in Every Note

You cannot see biofilm with the naked eye in most cases, which is precisely why documentation of indirect clinical indicators carries so much weight. The following findings should appear explicitly in every note where biofilm-directed treatment is planned.

The NERDS and STONEES Criteria in Practice

NERDS (Non-healing, Exudate increase, Red and bleeding granulation, Debris or yellow slough, Smell) indicates superficial critical colonization. STONEES (Size increasing, Temperature elevated, Os [bone exposed], New areas of breakdown, Exudate, Erythema/Edema, Smell) signals deeper infection.

Document these findings using the acronym structure or equivalent language. A note that reads "wound not progressing, yellow slough increased to 60% of wound bed, malodor noted" is more defensible than "chronic wound with signs of infection."

When documenting for billing purposes, include the following in every note:

Non-healing trajectory: Wound measurements over at least two visits showing stalled or worsening healing. Quantified sq cm values matter here — the same data supports skin substitute billing at the 2026 CMS flat rate of $127.14/sq cm when applicable.
Wound bed tissue type percentages: "50% slough, 30% fibrinous debris, 20% granulation" is quantified. "Sloughy wound bed" is not.
Exudate characteristics: Volume, color, and odor. "Moderate seropurulent exudate with foul odor" is specific. "Moderate drainage" is not.
Periwound changes: Erythema, edema, induration, warmth — measured in cm from wound edge where possible.
Response to prior treatment: "Wound debrided [date]; slough and fibrinous tissue returned to 55% of wound bed at [date] follow-up" establishes the biological basis for a recurrent debridement schedule.

Mapping Biofilm Documentation to the Right CPT Code

Biofilm documentation matters for CPT code selection as much as for LCD compliance. The choice between CPT 97597, CPT 11042, and higher-level codes depends on tissue depth — but the clinical findings you document must support the level billed.

For CPT 97597/97598 (selective debridement), the note needs to reflect:

Non-viable tissue present at the wound surface (slough, fibrin, debris)
A method consistent with selective debridement (sharp curette, enzymatic preparation, targeted irrigation)
Active clinical decision-making around tissue preservation versus removal

For a detailed breakdown of CPT 97597 billing requirements, including per-20-sq-cm increment billing and documentation thresholds, see the selective debridement billing guide.

For CPT 11042 and above (excisional debridement), the note must document involvement of the specific tissue layer — subcutaneous tissue, fascia, muscle, or bone. Biofilm-associated infection that has spread to subcutaneous tissue requires that finding stated explicitly, not inferred from surface description alone.

Mismatch between documented tissue depth and billed CPT code is the leading debridement audit trigger. If you bill CPT 11042 but the note only documents surface slough, you have a defensibility problem regardless of what was actually performed in the room.

For a complete map of the debridement code family and the documentation anchors for each level, see the wound care debridement billing guide.

Common Documentation Failures That Trigger Denials

Payer denials for debridement services follow a consistent pattern. If any of the following appear in your current documentation habits, address them before the next audit cycle.

Using infection language without supporting clinical criteria: Writing "wound infected" without documenting the specific clinical signs — or without a wound culture result — gives auditors grounds to question medical necessity. You can document "clinical signs consistent with critical colonization and superficial biofilm" without a culture, but you need the specific NERDS or STONEES findings to support that conclusion.

No comparison to prior visit: A single-visit snapshot does not establish that a wound is non-healing. Auditors look for trending data. If your EMR does not auto-populate prior measurements, manually reference the previous visit findings inline.

Vague treatment documentation: "Wound was debrided" is insufficient. Document the method, tissue removed, wound size before and after, any local anesthesia, and the patient's tolerance of the procedure.

Missing follow-up plan: LCDs typically require that the care plan address expected healing trajectory. "Continue wound care" is not a plan. "Biofilm-directed maintenance debridement every 7–14 days, goal to reduce slough burden and advance wound bed toward granulation" is.

Inconsistent documentation across visits: If visit one says 30% slough and visit two says 10% slough but you billed a second debridement, the notes must explain the clinical rationale for continuing treatment despite apparent improvement — or the improvement was overstated in the prior note.

Key Takeaways

Wound biofilm documentation is the clinical foundation for medically necessary debridement — without it, recurring claims are difficult to defend under LCD review.
Use NERDS and STONEES indicators and document specific percentages, tissue types, and wound measurement values in every encounter note.
Match CPT code selection to documented tissue depth; a mismatch between the note and the billed code is the most common debridement audit trigger.
Establish wound trajectory across multiple visits by explicitly referencing prior measurements and treatment response within the current note.
A maintenance debridement schedule is defensible when the note explains the biological rationale — biofilm reformation within 24–72 hours of disruption is that rationale.